Eli Lilly (LLY)
(Delayed Data from NYSE)
$760.00 USD
-11.55 (-1.50%)
Updated May 10, 2024 04:00 PM ET
After-Market: $760.50 +0.50 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 381 - 400 ( 426 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Solid Execution Overshadowed by Zyprexa Patent Expiration
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Griffin Securities Updates Coverage on Ligand Pharma. (LGND)
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Revenue down as Expected. First Quarter EPS Handily Exceeded Expectations
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Specialty Pharmaceuticals Short Interest Analysis
Provider: AURIGA USA
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Focus now to be on progression of R&D pipeline & several initial product data releases...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Fourth Quarter Results Felt the Impact of the Zyprexa Patent Expiration.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Raising our CY11 & CY12 estimates in view of strong performance in Q3 CY11........
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Third Quarter Revenue Increased 9% but Heavy Spending Led to Lower Earnings
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S